These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16005383)

  • 41. Increase in harm avoidance by genetic loading of schizophrenia.
    Sim M; Kim JH; Yim SJ; Cho SJ; Kim SJ
    Compr Psychiatry; 2012 May; 53(4):372-8. PubMed ID: 21696715
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Schizotypal symptoms in the relatives of schizophrenia patients: an empirical analysis of the factor structure.
    Bergman AJ; Silverman JM; Harvey PD; Smith CJ; Siever LJ
    Schizophr Bull; 2000; 26(3):577-86. PubMed ID: 10993399
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Patient modified medication: how do schizophrenic patients manage their neuroleptics?].
    Hornung WP; Buchkremer G; Redbrake M; Klingberg S
    Nervenarzt; 1993 Jul; 64(7):434-9. PubMed ID: 8103569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 45. What is specific to suicide in schizophrenia disorder? Demographic, clinical and behavioural dimensions.
    McGirr A; Turecki G
    Schizophr Res; 2008 Jan; 98(1-3):217-24. PubMed ID: 17942279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of neuroleptic on-drug response in schizophrenic in-patients by EEG.
    Ulrich G; Gaebel W; Pietzcker A; Müller-Oerlinghausen B; Stieglitz RD
    Eur Arch Psychiatry Neurol Sci; 1988; 237(3):144-55. PubMed ID: 2898366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The risk for psychiatric disorders in relatives of schizophrenic and control probands: a comparison of three independent studies.
    Kendler KS; Gardner CO
    Psychol Med; 1997 Mar; 27(2):411-9. PubMed ID: 9089833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Psychiatric morbidity in the first-degree relatives of schizophrenic patients.
    Varma SL; Sharma I
    Br J Psychiatry; 1993 May; 162():672-8. PubMed ID: 8149120
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prodromal states in schizophrenia.
    Gaebel W; Jänner M; Frommann N; Pietzcker A; Köpcke W; Linden M; Müller P; Müller-Spahn F; Tegeler J
    Compr Psychiatry; 2000; 41(2 Suppl 1):76-85. PubMed ID: 10746908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum.
    Garver DL; Holcomb JA; Christensen JD
    J Clin Psychiatry; 2000 Dec; 61(12):964-72; quiz 973. PubMed ID: 11206608
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Familial aggregation of mood disorders among relatives of schizophrenia probands admitted in a hospital in South-Eastern Nigeria: A family comparative study.
    Onu JU; Ohaeri JU
    Niger Postgrad Med J; 2018; 25(1):1-7. PubMed ID: 29676337
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mental illness in the biological and adoptive relatives of schizophrenic adoptees. Replication of the Copenhagen Study in the rest of Denmark.
    Kety SS; Wender PH; Jacobsen B; Ingraham LJ; Jansson L; Faber B; Kinney DK
    Arch Gen Psychiatry; 1994 Jun; 51(6):442-55. PubMed ID: 8192547
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The platelet polyphosphoinositide system in schizophrenia: the effects of neuroleptic treatment.
    Essali MA; Das I; de Belleroche J; Hirsch SR
    Biol Psychiatry; 1990 Sep; 28(6):475-87. PubMed ID: 1977477
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Elevated levels of schizotypal features in parents of patients with a family history of schizophrenia spectrum disorders.
    Appels MC; Sitskoorn MM; Vollema MG; Kahn RS
    Schizophr Bull; 2004; 30(4):781-90. PubMed ID: 15954190
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Schizotypal personality disorder inside and outside the schizophrenic spectrum.
    Torgersen S; Edvardsen J; Øien PA; Onstad S; Skre I; Lygren S; Kringlen E
    Schizophr Res; 2002 Mar; 54(1-2):33-8. PubMed ID: 11853976
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evoked gamma band synchronization and the liability for schizophrenia.
    Hong LE; Summerfelt A; McMahon R; Adami H; Francis G; Elliott A; Buchanan RW; Thaker GK
    Schizophr Res; 2004 Oct; 70(2-3):293-302. PubMed ID: 15329305
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A family study of nailfold plexus visibility in psychotic disorders.
    Clementz BA; Iacono WG; Ficken J; Beiser M
    Biol Psychiatry; 1992 Feb; 31(4):378-90. PubMed ID: 1558900
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Blink rate in childhood schizophrenia spectrum disorder.
    Caplan R; Guthrie D
    Biol Psychiatry; 1994 Feb; 35(4):228-34. PubMed ID: 7910486
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Familial-genetic and reproductive epidemiology of schizophrenia in rural Ireland: age at onset, familial morbid risk and parental fertility.
    Waddington JL; Youssef HA
    Acta Psychiatr Scand; 1996 Jan; 93(1):62-8. PubMed ID: 8919331
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thought disorder in schizophrenic and control adoptees and their relatives.
    Kinney DK; Holzman PS; Jacobsen B; Jansson L; Faber B; Hildebrand W; Kasell E; Zimbalist ME
    Arch Gen Psychiatry; 1997 May; 54(5):475-9. PubMed ID: 9152101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.